MedPath

Clinical Trial News

Jacobio Pharmaceuticals Initiates Clinical Trial for Novel Cancer Drug

  • Jacobio Pharmaceuticals has commenced a clinical trial for a new cancer drug, marking a significant step in their oncology program.
  • The trial aims to evaluate the safety and efficacy of the drug in a specific patient population, contributing to the advancement of cancer treatment options.
  • This development underscores Jacobio's commitment to innovative research and development in the pharmaceutical sector, potentially addressing unmet medical needs.
  • The initiation of this trial represents a key milestone for Jacobio, with potential implications for future cancer therapies and patient outcomes.

Toripalimab Plus Chemotherapy Shows Promise in Advanced Pancreatic Cancer

  • A phase Ib/II study reveals that toripalimab combined with gemcitabine and nab-paclitaxel (GnP) demonstrates promising efficacy in patients with advanced pancreatic ductal adenocarcinoma (PDAC).
  • The combination therapy achieved an objective response rate (ORR) of 33.3% and a disease control rate (DCR) of 90.3% in the intent-to-treat population.
  • Spatial analysis of the tumor microenvironment (TME) identifies immune niches, particularly IN-8, as potential predictors for immunotherapy response, characterized by interactions between dendritic cells (DCs), cytotoxic T lymphocytes (CTL), and T helper cells (Th).
  • Baseline serum IL-8 levels may serve as a predictive biomarker for treatment response, with lower levels associated with better outcomes in patients undergoing chemotherapy combined with immunotherapy.

Innovent Highlights IBI343 Data in Pancreatic Cancer at ESMO Asia 2024

  • Innovent will present clinical data on novel oncology molecules at the ESMO Asia Congress 2024, showcasing advancements in cancer treatment.
  • Updated Phase 1 results of IBI343, a TOPO1i CLDN18.2 ADC, will be presented, demonstrating encouraging efficacy and safety in previously-treated pancreatic cancer.
  • The company is also presenting data on combination therapies involving sintilimab and anlotinib in various cancer types, including colorectal and lung cancer.
  • Innovent is dedicated to transforming cancer treatment by delivering innovative, effective, and safe therapeutic options for doctors and patients.

Argenx's Myositis Trial Data Prompts Optimistic Outlook from Jefferies

  • Argenx reported positive data across all myositis subsets in a recent trial, showing clear signals in both primary and secondary endpoints, including time to response.
  • Jefferies reaffirmed its Buy rating on argenx, raising the price target to $707.00, citing the promising trial updates and the potential for quick adjustments to the Phase 3 study.
  • Argenx is expanding indications for Vyvgart, considering moving directly to Phase 3 trials with Zai Lab partnership data, and focusing on achieving operating leverage with SG&A expense discipline.
  • Analyst upgrades from Oppenheimer, Barclays, Raymond James, Wolfe Research, and Scotiabank reflect confidence in argenx's performance, particularly in myasthenia gravis (MG) and efgartigimod's potential.

SSY Group Receives Approval for Compound Sodium Acetate and Glucose Injection in China

  • SSY Group has secured approval from China's National Medical Products Administration for its Compound Sodium Acetate and Glucose Injection.
  • The drug is classified as a type 3 chemical drug and has passed consistency evaluation, placing SSY Group among the first manufacturers in China with this approval.
  • The injection is designed to replenish and maintain water and electrolytes, as well as provide energy when oral administration is not feasible.
  • This approval marks a significant advancement in SSY Group's business development, offering a new treatment option for patients requiring intravenous hydration and electrolyte balance.

Advances in HIV Treatment: From Novel Prevention to Potential Cures

  • A novel nanomedicine using siRNAs targeting CCR5 and Nef shows promise in preventing HIV sexual transmission by blocking viral entry and reactivating autophagy.
  • An HIV-virus-like particle (HLP) therapeutic can reactivate dormant HIV in immune cells, making them susceptible to cART and the immune system, potentially curing HIV.
  • Despite advancements, challenges remain in HIV management, including global disparities in treatment access, drug resistance, and the virus's ability to establish latent reservoirs.

FDA Approves Rystiggo (rozanolixizumab-noli) for Generalized Myasthenia Gravis

  • The FDA has approved Rystiggo (rozanolixizumab-noli) for treating generalized myasthenia gravis (gMG) in adults with specific antibody-positive subtypes.
  • Rystiggo, a humanized IgG4 monoclonal antibody, reduces circulating IgG levels by binding to the neonatal Fc receptor (FcRN).
  • Clinical trials demonstrated statistically significant improvements in MG-ADL and QMG scores with Rystiggo compared to placebo.
  • The most common adverse reactions reported were headache, infections, diarrhea, pyrexia, hypersensitivity reactions, and nausea.

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

NCT05681715CompletedPhase 3
UCB Biopharma SRL
Posted 4/17/2023

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

NCT03971422CompletedPhase 3
UCB Biopharma SRL
Posted 6/3/2019

Alpheus Medical's Sonodynamic Therapy Shows Promise in Recurrent High-Grade Gliomas

  • Alpheus Medical announced positive Phase 1/2 trial results for its sonodynamic therapy (SDT) in recurrent high-grade gliomas, demonstrating a strong safety profile.
  • The trial showed extended median overall survival (15.7 months) and progression-free survival (5.5 months) compared to historical data for this aggressive brain cancer.
  • Alpheus's SDT combines low-intensity ultrasound with oral 5-aminolevulinic acid, offering a non-invasive treatment option that can be administered in an outpatient setting.
  • A randomized, controlled trial is planned for 2025 to further evaluate the efficacy of Alpheus Medical's SDT platform in treating recurrent high-grade gliomas.

Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma

NCT05362409CompletedPhase 1
Alpheus Medical, Inc.
Posted 6/29/2022

Avapritinib Approved for Advanced Systemic Mastocytosis, Offering New Hope to Patients

  • Avapritinib, a novel drug, has been approved for treating advanced systemic mastocytosis (ASM) by the UK's NICE.
  • Clinical trials demonstrated that Avapritinib cleared the disease in a third of patients and significantly improved symptoms in almost all others.
  • The once-daily pill targets the KIT mutation in bone marrow cells, which drives the cancer, leading to improved quality of life and survival.
  • This approval marks a significant advancement in treating ASM, a rare and deadly blood cancer with limited treatment options.

Neurotech International's NTI164 Shows Promise in Pediatric Neurological Disorders

  • Neurotech International is progressing with trials of NTI164, a drug targeting pediatric neurological disorders, showing potential in improving neural network function.
  • The drug aims to modulate neuroinflammation and enhance neuroprotection, addressing critical unmet needs in conditions like Autism Spectrum Disorder and Cerebral Palsy.
  • Clinical trials are underway to evaluate NTI164's efficacy in improving cognitive and motor functions, with initial data suggesting positive trends in treated patients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.